Drug Database
DI

diltiazem (Cardizem SR / Corolater)

✓ Approved

Bausch Health Companies Inc. · CACNA1C · 小分子

什么是 diltiazem?

diltiazem 是一种小分子,由Bausch Health Companies Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Cardizem SR, Corolater
公司Bausch Health Companies Inc.
药物类别小分子
分子靶点CACNA1C
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

diltiazem 作用于 1 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

diltiazem 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Cardiac disordersAngina pectoris✓ Approved

相关研究文献

PubMedBMC oral health2026-11-19

Oral health behaviours and shift work barriers among Hungarian EMS personnel: a cross-sectional study.

Mühl Attila A, Prugberger József J, Kovács Edit E, Németh Orsolya O

Shift-working emergency medical services (EMS) personnel face structural barriers to preventive oral care, yet national workforce data remain scarce. To estimate prevalence of oral symptoms, behaviours, dental attendance, and psychosocial OHRQoL impacts among Hungarian National Ambulance Service (OMSZ) staff; assess associations with occupational enablers/barriers; and evaluate acceptability of employer-supported screening. Nationwide cross-sectional anonymous online survey (13 Sep 2024-17 Apr 2025; n = 1,061; 73% men, 74% 24-hour shifts). Logistic regression examined a priori outcomes (ORs, 95% CI), adjusted for age/sex/attendance; STROBE-compliant. Among 1,061 respondents, 74% reported 24-hour shifts as their primary duty pattern. Over half reported current or recent dental/oral problems (54.9%), and 20% had not attended a dental check-up within the previous two years. Off duty, 33% brushed twice daily, whereas during duty about two-thirds reported regular brushing. Workplace hygiene kits were reported by 40% of respondents and were more common among 24-hour shift workers. In regression analyses, kit availability was strongly associated with daily or more frequent on-duty brushing among 24-hour staff (85% vs. 21%). Daily brushing was associated with lower odds of toothache, non-use of interdental cleaning with higher odds of hiding teeth, and rare on-duty brushing with higher odds of halitosis. Psychosocial impacts were similar across roles, and 88-90% were willing to undergo workplace screening. Shift-constrained EMS staff face substantial, preventable oral health burdens amenable to occupational solutions. Enabling on-duty hygiene and supporting routine care are key priorities. High screening readiness supports integrating teledentistry. Consistent gaps across roles underscore the need for further longitudinal and interventional studies.

PMID 43052941
阅读全文 →
PubMedPharmacotherapy2026-11-19

Selexipag as a Therapeutic Alternative for Treprostinil-Induced Thrombocytopenia in Pulmonary Arterial Hypertension: A Case Report.

Kido Kazuhiko K, Madgula Anantha A, Coons James C JC, Caccamo Marco M et al.

Parenteral prostacyclin pathway agent-induced thrombocytopenia may require dose reduction or therapy discontinuation to mitigate the adverse events. However, the pulmonary arterial hypertension (PAH) guidelines do not suggest any strategy to overcome treprostinil-induced thrombocytopenia. Selexipag is an oral, non-prostanoid, selective IP receptor agonist. This is the first case report proposing the use of selexipag, due to its minimal thrombocytopenia risk, when severe treprostinil-induced thrombocytopenia occurs in practice. A 66-year-old woman presented to the hospital with new-onset PAH and right ventricular dysfunction. Due to the high mortality risk, the patient was initially started on intravenous treprostinil. The clinical course was complicated by probable treprostinil-induced thrombocytopenia. Due to the need for prostacyclin pathway therapy, the decision was made to switch from intravenous treprostinil to oral selexipag. The nadir platelet count was 30,000/μL. Approximately 72 h after discontinuation of treprostinil and maintaining selexipag 1600 mcg twice daily, the platelet count improved to 46,000/μL on the day of discharge. Several days after discharge, the platelet count further improved to 55,000/μL. The repeated platelet count 1 month after discharge normalized to 329,000/μL. Our case report described the successful use of selexipag to overcome treprostinil-induced thrombocytopenia, owing to its limited effect on platelet aggregation.

PMID 43053638
阅读全文 →
PubMedBMC oral health2026-11-19

Differences in self-reported orofacial pain and daily activities between children surveyed in metropolitan and provincial areas of Japan: a school-based cross-sectional survey.

Karibe Hiroyuki H, Okamoto Ayuko A, Shimazu Kisaki K, Kawakami Tomomi T et al.

Orofacial pain (OFP) in children may be associated with daily activities and psychological factors; however, these characteristics may vary across geographical settings. Evidence regarding geographical differences in OFP and related daily activities among Japanese children remains limited. This study aimed to compare self-reported OFP characteristics, daily activities, and trait anxiety between children surveyed in one metropolitan area and one provincial area in Japan. This school-based cross-sectional survey included 923 children aged 11-12 years from selected elementary schools in a metropolitan area (MA; n = 480) and a provincial area (PA; n = 443). Data were collected in 2011-2012. Participants self-reported TMD-related symptoms, headache, neck pain, and toothache. Daily activities were assessed using a 15-item questionnaire and trait anxiety using the State-Trait Anxiety Inventory for Children-Trait (STAIC-T). Group differences were examined using t-tests, chi-square or exact tests. Associations with headache and neck pain were examined using univariable and multivariable logistic regression. Geographical area × daily-activity interactions were tested in the pooled sample with false discovery rate (FDR) correction. Age, sex distribution, STAIC-T scores, and the prevalence of self-reported TMD symptoms and toothache did not differ significantly between the geographical samples. Headache and neck pain were reported more frequently in the MA sample than in the PA sample (p = 0.035 and p = 0.002, respectively). Several daily activities were associated with headache and/or neck pain in area-stratified multivariable analyses. In formal interaction analyses, only the association between use of a high pillow and headache differed significantly between the geographical samples after FDR correction; no daily-activity interaction for neck pain remained significant after FDR correction. Children surveyed in the metropolitan area reported headache and neck pain more frequently than those surveyed in the provincial area. Several self-reported daily activities were associated with headache and/or neck pain, although these associations should not be interpreted as causal or necessarily specific to either geographical area. Given the cross-sectional design, reliance on self-reported measures, and sampling from selected geographical areas, these findings should be interpreted cautiously and require confirmation in contemporary longitudinal studies.

PMID 43052909
阅读全文 →
PubMedJournal of health, population, and nutrition2026-11-19

Self-reported health-related quality of life among regular multivitamin-mineral supplement users: a weighted pooled observational analysis of 2,600 adults from four Asia Pacific countries.

Tan Min Min MM, Chong Jian Hui JH, Yee Shi Mun SM, Gadzhieva Aida A et al.

Multivitamin-mineral (MVM) supplements are widely used across the Asia Pacific; however, real-world, validated patient-reported evidence on immune function, mental well-being and energy remains limited. The aim of the study is to evaluate the relationship between daily MVM consumption and quality of life using validated patient-reported outcomes (PROs) measures across pooled adult cohorts in the Asia-Pacific region and assess perceived immune and energy support among daily versus non-daily MVM users. We conducted a pooled analysis of four cross-sectional surveys from Australia, South Korea, the Philippines, and Taiwan (N = 2,600) among adult (20-65 years) existing users of the Centrum MVM supplement. The primary outcomes were validated PRO, including immune function (Immune Status Questionnaire [ISQ] < 6), mental well-being (WHO-5 Well-Being Index < 13) and energy level (SF-36 Vitality Scale). Secondary outcome included perceived immune and energy support. Data were harmonized and post-stratification weighted by location and sex. Survey-weighted multivariable logistic and linear regression models assessed associations between daily MVM use and PROs, adjusted for age, sex, income and location, with effect modification by age group. A higher proportion of daily MVM users reported agreement that MVM supplementation supports immunity (85.4% vs. 81.7%) and energy (84.8% vs. 79.5%). Differences across the full response distributions were statistically significant (p < 0.001). For immune support, adults 40 years and older showed significantly higher agreement (85.8% vs. 82.8%, p < 0.001), while for energy support, daily use was associated with higher agreement across all age groups, particularly those under 40 years (87.4% vs. 81.5%, p = 0.005). These perceived benefits were consistent with findings from PROs: most users reported normal immune function (ISQ ≥ 6), and daily MVM use was associated with lower odds of reduced immune function (odds ratio [OR] 0.79, 95% CI 0.64-0.98) and poor mental well-being (OR 0.72, 95% CI 0.58-0.89), as well as higher Vitality Scale score (adjusted mean difference 3.29 points, 95% CI 1.91-4.68). Associations were generally consistent across age subgroups. Item-level analyses showed more frequent endorsement of positive well-being and perceived energy levels among daily users. Daily MVM supplement use in Asia Pacific cohorts was associated with greater perceived health benefits, better well-being, and perceived energy levels, supporting its relevance in real-world settings.

PMID 43053146
阅读全文 →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-19

Efficacy and safety of adjunctive use of rifaximin in preventing radiotherapy-induced diarrhea in cancer patients: a randomized controlled trial.

El-Maghraby Menna A MA, Mansour Noha O NO, Eldesoky Ahmed Ramadan AR, Soliman Moetaza M MM

Radiation-induced diarrhea (RID) is a common, dose-limiting toxicity in patients with pelvic cancer undergoing radiotherapy. No pharmacological agent is currently approved for its prevention. Rifaximin, a non-absorbable antibiotic with anti-inflammatory and microbiota-modulating properties, may offer protective benefits. This prospective, parallel-group, open-label randomized controlled trial enrolled 80 adults with non-metastatic pelvic cancers receiving curative-intent radiotherapy, with or without chemotherapy. Participants were randomized in 1:1 ratio to receive standard care alone or standard care plus rifaximin 550 mg twice daily throughout radiotherapy. Primary outcome was the incidence of grade ≥ 2 diarrhea assessed by Common Terminology Criteria for Adverse Events (CTCAE v5.0). Secondary outcomes included time to diarrhea onset, stool consistency (Bristol scale), dehydration, quality of life assessed using European Organization for Research and Treatment of Cancer questionnaire (EORTC QLQ-C30), and safety. Patients' follow-up lasted 3 months post-radiotherapy. Seventy-eight patients completed the study. Incidence of grade ≥ 2 diarrhea was comparable between groups (23.1% control vs. 17.9% rifaximin; risk difference [95% CI] - 5.1 [ - 23.0, 12.8]). Time to onset and rescue medication use did not differ significantly. Stool consistency and dehydration rates were comparable. Rifaximin significantly improved global health status at end of radiotherapy (mean difference between control and rifaximin groups [95% CI] - 10.5 [ - 18.5, - 2.4]) and at three months (- 7.0 [ - 13.1, - 1.0]), with lower fatigue (14.5 [4.2, 24.9]) and pain scores (12.8 [3.1, 22.5]). Adverse events were mild and comparable between groups. Adjunctive rifaximin did not reduce incidence or severity of RID but was associated with improved quality of life and symptom burden. Rifaximin was well tolerated. Larger, double-blind trials are warranted to confirm these findings and explore optimized dosing and timing of administration. Registration of the study: https://clinicaltrials.gov/study/NCT06783153.

PMID 43052387
阅读全文 →
PubMedBMC cardiovascular disorders2026-11-19

Sleeping with the unknown: coronary vasospasm in an anomalous right circumflex artery mimicking in-stent restenosis.

Ali Fahad F, Kelly Jordan J, Karar Mohamed M, Elzain Hassan H et al.

Coronary vasospasm represents a transient, reversible constriction of coronary arteries that often goes unrecognised in patients with established coronary artery disease or anomalous coronary anatomy. When combined with prior percutaneous coronary intervention (PCI), vasospasm can closely mimic in-stent restenosis, leading to delayed diagnosis and unnecessary repeat interventions. We describe a 55-year-old male with prior PCI to an anomalous right circumflex artery (RCx) who presented with recurrent nocturnal chest pain and asymptomatic transient ST-segment elevation (STE) during sleep. Despite FFR-guided PCI to the left anterior descending artery (LAD) and subsequent repeat intervention for suspected RCx in-stent restenosis, symptoms persisted. A probable diagnosis of nocturnal coronary vasospasm was established based on the clinical presentation, characteristic nocturnal ECG changes, response to diltiazem, and exclusion of alternative structural pathology on cardiac magnetic resonance imaging; however, the diagnosis remains inferential in the absence of invasive provocation testing. This case illustrates the diagnostic complexity of probable coronary vasospasm in a male patient with structural coronary disease and anomalous coronary anatomy. Several factors may have contributed to diagnostic delay, including anchoring toward structural disease, angiographic ambiguity, anomalous anatomy, and the unusual nocturnal presentation. The differential response to calcium channel blocker subclasses in this patient is presented as a clinically relevant, hypothesis-generating observation rather than evidence of therapeutic superiority. Clinicians should maintain a high index of suspicion for probable coronary vasospasm in patients with recurrent nocturnal ST elevation following PCI, particularly when symptoms, telemetry findings, and coronary physiology are discordant with fixed obstructive disease. Careful reassessment, transparent acknowledgement of diagnostic uncertainty, and thoughtful use of non-invasive monitoring and targeted medical therapy may help avoid unnecessary repeat intervention.

PMID 43052750
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diltiazem